Sign in
Not yet recruitingPhase 3

Women Who Are Victims of Violence: Treatment of PTSD Through Reactivation of Traumatic Memories Using Propranolol

Key facts

Who runs it
University Hospital, Toulouse
Where
France2 sites in 1 countryChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 3
People taking part
70 people, planned
Starts
Dec 2026
Expected to end
Mar 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Propranolol
  • Psychotherapy
Record updated
6 November 2026

Who can take part

Age
18 years to 75 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Women aged from 18 to 75 years
  • Having been victim of severe violence (rape, sexual assault, physical assault) Currently suffering from PTSD related to the traumatic event. The diagnosis of PTSD is made according to the DSM-5 criteria by a psychiatrist/psychologist using the CAPS-5, regardless of the traumatic event meeting criterion A of the DSM-5, with or without dissociative symptoms as described in the "With dissociative symptoms" section of the DSM-5, Immediate or delayed PTSD CAPS-5 total score ≥ 33 heart rate ≥ 55 bpm
  • The subject must have signed the consent form
  • The subject must be enrolled in a social security program
  • The participant must be able to understand and read French
  • The participant agrees to comply with the contraception requirements outlined in the protocol

Who cannot take part

  • Previous intolerance to a beta-blocker
  • Undergoing psychotherapy or pharmacological treatment with psychotropic agents such as antidepressants, neuroleptics, and/or mood stabilizers. However, these subjects may be included after a 2-week therapeutic abstinence period (6 weeks for treatment with fluoxetine)
  • Contraindications to the administration of propranolol: Asthma, Chronic obstructive pulmonary disease, Decompensated heart failure, Cardiogenic shock, Unpaced second-degree atrioventricular block, Unpaced third-degree atrioventricular block, Spasmodic angina, Uncompensated sinus node dysfunction, bradycardia, Raynaud's syndrome, severe peripheral circulatory disorder, untreated pheochromocytoma, arterial hypotension, hypersensitivity to beta-blockers, history of anaphylactic allergic reaction
  • Heart failure (compensated or decompensated)
  • Severe liver disease
  • Significant renal impairment
  • Personal or family history of psoriasis
  • Severe psychiatric disorders: Severe symptoms of other anxiety disorders, severe symptoms of Obsessive-Compulsive Disorder, history of or current psychotic disorder, bipolar mood disorder, severe personality disorder, alcohol or other substance use disorder
  • Women of childbearing age not using contraception
  • Systolic blood pressure below 100 mm Hg
  • Myasthenia gravis
  • Patients who have suffered a head injury within the past year or who have clinical symptoms and residual neurological sequelae
  • Wearing contact lenses
  • "Yes" response to item 4 of the C-SSRS: active suicidal ideation with intent to act, without a specific plan, and/or "Yes" response to item 5 of the C-SSRS: active suicidal ideation with a specific plan and intent to act
  • Hospitalized or treated for suicidal behavior within the past 3 months
  • Pregnancy, breastfeeding
  • Current use of a beta-blocker, regardless of the formulation
  • Known interactions with Propranolol (combination use not recommended and combinations to be used with caution) as indicated in the summary of product characteristics
  • Patients under judicial protection, under guardianship or curatorship, individuals under family authorization, or under a future protection order with representation regarding the person
  • Participants who are related to a person involved in the study at the investigator's center, within the clinical research organization (CRO), or at the sponsor
  • Participation in another interventional research study, clinical trial, or clinical investigation within the 6 months preceding selection

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Post-traumatic stress disorder (PTSD) develops after life-threatening events, with domestic violence and sexual assault being major risk factors. An innovative approach using traumatic memory reactivation with propranolol has shown promise in reducing PTSD symptoms. This study aims to compare the efficacy of propranolol with trauma-focused psychotherapy in women suffering from severe PTSD after violence.

The 2 groups in the trial

  • Propranolol groupTreatment being tested

    Treatment: Propranolol

  • Psychotherapy groupExisting treatment, for comparison

    Treatment: Psychotherapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Fit questions
Built from NCT07792122, who can take part
Record updated
6 November 2026